According to official statistics from the WHO in 2022, oncological diseases are now the cause of one in every six deaths worldwide. This has encouraged the international medical community to develop new cancer treatment methods and increase the effectiveness of the already existing ones.

Therapeutic radionuclides Lutetium-177-PSMA, Actinium-225-PSMA, and Radium-223 have been successfully used in the treatment of advanced prostate cancer. These are modern drugs, in the development of which scientists have corrected the shortcomings of earlier used isotopes. With Actinium-225 emerging as a promising alternative to...

Prostate cancer is the most widespread type of oncological pathology among men. Doctors from all over the world pay attention to timely prophylaxis and diagnostics because at the early stages this disease is treated much easier. When the process is beyond the stage 1-3, especially when there are metastases in other organs and the skeleton...

Oncolytic virotherapy is an innovative cancer treatment that utilizes viruses to selectively infect and destroy cancer cells while simultaneously stimulating a systemic antitumor immune response. Since its emergence as a form of immunotherapy, oncolytic virotherapy has rapidly gained relevance in oncology. In 2015, the FDA approved Imligic...

Prostate cancer is one of the most common oncological diseases worldwide, affecting millions of men each year. According to global cancer statistics, prostate cancer is the second most diagnosed cancer among men and ranks as the fifth leading cause of cancer-related deaths. Despite these alarming numbers, prostate cancer is treatable...

Benign prostatic hyperplasia is one of the most common urological conditions in men, especially aged 50 and older. The number of cases of BPH is rapidly increasing worldwide. According to the data published in The Lancet, the distribution of the disease according to age is as follows: 8% in their 40s, 50% in their 60s, and 80% in...

Immunotherapy for melanoma is the treatment of choice for patients with metastatic tumors, resistance to chemotherapeutic agents, and disease recurrence after the successful initial treatment. Vaccination with dendritic cells reboots a person's immunity, teaching it to find and attack melanoma cells throughout the body.

Colon cancer (ICD C18) is one of the five most common malignant tumors in the world, ranking third overall. While the average age of most patients is 60-75 years, the disease can also develop in individuals between 35-50 years old. Favorable treatment outcomes and colon cancer prognosis, even at stage 4 cancer, can be achieved with the usage...